The following article is a part of conference coverage from the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, being held in Atlanta, Georgia. The team at Rheumatology Advisor will be reporting on the latest news and research conducted by leading experts in rheumatology. Check back for more from the 2019 ACR/ARP Annual Meeting.


ATLANTA – Blockage of tumor necrosis factor alpha (TNFα) and interleukin (IL)-12/23 was associated with a significant improvement in depressive symptoms in patients with psoriatic arthritis (PsA), according to study results presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, held November 8 to 13, 2019, in Atlanta, Georgia.

Related Articles

Investigators collected data from 3 randomized controlled trials assessing the efficacy of golimumab (TNFα blocker) and ustekinumab (IL-12/23 blocker). The GO-REVEAL trial assessed golimumab, and the PSUMMIT1 and PSUMMIT2 trials assessed ustekinumab. Study assessments were conducted at baseline, between weeks 14 and 16, and at week 24. The Short-Form Health Survey (SF-36) mental component summary score was used to capture change in depressive symptoms during the trial period; SF-36 scores <38 defined a state of depression. A chi-squared test (odds ratio [OR]) was used to calculate the change in percentage of patients with depression from baseline through follow-up.

The pooled study cohort from the 3 trials comprised data of 1332 patients (mean age, 47 years; women, 39.8%-52.6%). At baseline, the percentage of patients classified as having depression were 29.4%, 34.9%, and 38.8% in the GO-REVEAL, PSUMMIT1, and PSUMMIT2 trials, respectively.


Continue Reading

A significant decrease in the percentage of patients with depression was observed in the treatment arms of all 3 studies. In the GO-REVEAL study, the proportion of depression in the golimumab arm declined from 31.2% at baseline to 19.5% at week 14 (OR, 0.54; P =.001) and 15.8% at week 24 (OR, 0.41; P <.001). In the ustekinumab arm of the PSUMMIT1 trial, the percentage of patients with depression decreased from 36.2% at baseline to 23.5% at week 16 (OR, 0.54; P<.001) and 20.3% at week 24 (OR, 0.45; P <.001). In the PSUMMIT2 trial, a similar trend was observed in the ustekinumab arm: 37.5% of patients had depression at baseline, compared with just 25.5% at week 14 (OR, 0.57; P =.009) and 21.2% at week 24 (OR, 0.45; P <.001).

The placebo arm in all 3 studies showed minimal changes in the proportion of depression.

“Blockage of TNFα and IL-12/23 was associated with a significant improvement in depressive symptoms in patients with PsA participating in clinical trials,” the researchers concluded.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.

Visit Rheumatology Advisor for live coverage and more news from the 2019 ACR/ARP Annual Meeting.


Reference

Eder L, Ogdie A, Zhong Y. Blockage of TNFα and IL-12/23 improves depressive symptoms in patients with psoriatic arthritis – analysis of clinical trial data. Presented at: 2019 ACR/ARP Annual Meeting; November 8-13, 2019; Atlanta, GA. Abstract 1490.